---
title: "DBV Technologies S.A. (DBVT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DBVT.US.md"
symbol: "DBVT.US"
name: "DBV Technologies S.A."
industry: "Biotechnology"
datetime: "2026-05-19T19:23:14.836Z"
locales:
  - [en](https://longbridge.com/en/quote/DBVT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DBVT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DBVT.US.md)
---

# DBV Technologies S.A. (DBVT.US)

## Company Overview

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.dbv-technologies.com](https://www.dbv-technologies.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 110 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 61.85% |  |
| Net Profit YoY | -47.31% |  |
| P/B Ratio | 4.25 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 883486068.75 |  |
| Revenue | 5736000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -158.89% | E |
| Profit Margin | -2919.23% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 61.85% | A |
| Net Profit YoY | -47.31% | D |
| Total Assets YoY | 426.88% | A |
| Net Assets YoY | 7136.34% | A |
| Cash Flow Margin | 89.93% | C |
| OCF YoY | 61.85% | A |
| Turnover | 0.04 | E |
| Gearing Ratio | 21.96% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - DBV Technologies S.A.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "61.85%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-47.31%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.25",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "883486068.75",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5736000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-158.89%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2919.23%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "61.85%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-47.31%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "426.88%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "7136.34%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "89.93%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "61.85%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "21.96%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.28 | 382/386 | - | - | - |
| PB | 4.25 | 300/386 | 21.79 | 9.45 | 4.42 |
| PS (TTM) | 154.02 | 269/386 | 173.90 | 106.96 | 70.69 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 67% |
| Overweight | 1 | 17% |
| Sell | 1 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.46 |
| Highest Target | 55.03 |
| Lowest Target | 5.99 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DBVT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DBVT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DBVT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DBVT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**